Metrics as of 10/16/2026, 06:03 AM (Berlin time), refresh in progress.
Rocket Pharmaceuticals Stock
Rocket Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gaurav D. Shah
- Employees
- 202
- Market cap
- $259 M
- IPO
- 18/02/2015
Rocket Pharmaceuticals, Inc. is a U.S.-based healthcare/biotechnology company headquartered in Cranbury, New Jersey. The focus lies on developing innovative gene therapies for rare and serious diseases. Its clinical pipeline includes several programs, such as ex vivo lentiviral vector therapies for the treatment of…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Rocket Pharmaceuticals stock: price history
1D
+6.8%
1W
-10.3%
1M
-30.8%
6M
-39.5%
YTD
-32.8%
1Y
-44.3%
2Y
-85.9%
5Y
-91.5%
10Y
-92.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~27% weaker price swings than usual
Rocket Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Rocket Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing gene therapies for rare and severe genetic diseases. The clinical pipeline comprises programs for treating Fanconi anemia, leukocyte adhesion deficiency I, and pyruvate kinase deficiency using ex vivo lentiviral vectors, as well as an in vivo program for Danon disease. In support of its research and development efforts, the company maintains collaborations with institutions such as the Fred Hutchinson Cancer Research Center and REGENXBIO, Inc. As the company is primarily in the clinical stage, it currently generates no revenue from product sales.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Efficient scale
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Rocket Pharmaceuticals
Analyst assessment of Rocket Pharmaceuticals
PRICE TARGET LOW
US$2.95
CONSENSUS
US$5.32
MEDIAN
US$4.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
14
BUY
4
HOLD
1
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 08/10/2026
Rocket Pharmaceuticals stock metrics
P/E
-14.75
P/B
0.72
EV/EBITDA
10.23
RETURN ON EQUITY
33.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.8%
FLOAT SHARES
87,618,790
AVG. DAILY VOLUME (30D)
2,085,046
Insider transactions (SEC)
Wilson Martin
Wilson Martin
Shah Gaurav
Shah Gaurav
Wilson Martin
Attention
Price since yesterday: +6.8%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Rocket Pharmaceuticals stock
What does Rocket Pharmaceuticals do?
Rocket Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gaurav D. Shah, the company employs around 202 people.
The IPO was on 18/02/2015; the stock trades on NASDAQ under the ticker RCKT.
What do analysts say about Rocket Pharmaceuticals stock?
19 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$5.32, ranging from US$2.95 to US$9.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Rocket Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -27% stronger than usual.
Does Rocket Pharmaceuticals pay a dividend?
No, Rocket Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Rocket Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Rocket Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Rocket Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.